IGF1 and retinal disorder: And thirdly, although Rosenbloom[384] stated that the rhIGF-I insulin-sensitizing effect may be beneficial for diabetic patients to reduce hemoglobin A1C levels, there are no current ongoing clinical trials because of concern about risk of retinopathy and other complications[425], thus limiting the theoretically wide spectrum of potential IGF-I treatment indications.